/PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it.
– Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key.
– Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third.
– Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenue of $29.0 Million, a.
– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable.